Phase II study of erlotinib monotherapy for patients with advanced stage of non-small cell lung cancer, undetectable epidermal growth factor receptor (EGFR) mutations by PNA LNA PCR clamp method, but positive immuno-staining with anti-EGFR mutation-specific antibodies.
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2016
Price : $35 *
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Aug 2016 Status changed from recruiting to discontinued.
- 23 Jul 2014 New trial record